Moderately Hypofractionated Radiotherapy for Prostate Cancer.

Prostatic Neoplasms Clinical Trial

Official title:

A Prospective Randomized Phase II Clinical Trial of Moderately Hypofractionated Radiotherapy (70 Gy in 28 Fractions vs 60 Gy in 20 Fractions) Using Helical Tomotherapy.

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03827616
• Other study ID #: prostata116
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: January 25, 2019
• Est. completion date: February 1, 2030

Study information

• Verified date: February 2019
• Source: Tatarstan Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Radiation therapy is one of the standard treatments for men with prostate cancer. Moderately hypofractionated radiotherapy has been established to be equivalent to standard fractionated radiotherapy in several large randomized clinical trials, however different hypofractionated regimens have been used in these studies. The two most common hypofractionated regimens are 70 Gy in 28 fractions and 60 Gy in 20 fractions, both are considered standard of care, however it is not unknown which regimen is better in terms of effectiveness and toxicity. The aim of this randomized controlled clinical trial is to compare the two hypofractionated radiotherapy regimens using Helical Tomotherapy.

Description:

OBJECTIVES:

Primary

Compare the biochemical relapse free survival (DFS) of patients with prostate cancer treated with hypofractionated regimens 70 Gy in 28 fractions and 60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.

Secondary

Compare time to local progression, freedom from biochemical recurrence, and disease-specific and overall survival of patients treated with these regimens.

Determine the incidence of gastrointestinal and genitourinary toxic effects in patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are stratified according to TNM ( T1-3N0M0), Gleason score (6,7 (3+4), 7(4+3), 8). Before radiotherapy patients receive hormone therapy from 3 months to 6 months. Patients are randomized to 1 of 2 treatment arms.

Arm 1 hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy

• 50,4 Gy).

Arm II hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 200
• Est. completion date: February 1, 2030
• Est. primary completion date: February 1, 2029
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 100 Years

Eligibility

Inclusion criteria:

1. Histologically confirmed adenocarcinoma of the prostate. 2 The presence of the following studies: TRUS of the prostate gland, pelvis MRI, OSG.

3 Histological evaluation of prostate biopsy with assignment of the Gleason index.

4 Clinical stage T1-3N0M0 (AJCC 7th edition). 5 ECOG performance status 0-1 6 Age limit 18 years. 7 Patient consent to participate in a clinical study.

Exclusion criteria:

1. Prior or concurrent lymphomatous/hematogenous malignancy or other invasive malignancy except nonmelanomatous skin cancer or any other cancer for which the patient has been continually disease-free for = 5 years (e.g., carcinoma in situ of the bladder or oral cavity)

2. Distatnt metastases.

3. Metastases in the lymph nodes of prostate cancer.

4. Radical prostatectomy or cryodestruction of the prostate gland in history.

5. Radiation of a small pelvis in the anamnesis. Bilateral orchectomy history.

6. Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months, transmural myocardial infarction within the past 6 months, acute bacterial or fungal infection requiring IV antibiotics, chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study treatment, hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.

Related Conditions & MeSH terms

• Genital Neoplasms
• Neoplasms
• Prostatic Neoplasms

Intervention

Radiation:
• Hypofractionated IMRT using helical Tomotherapy.
70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
• Hypofractionated IMRT using helical Tomotherapy.
60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.

Locations

Country	Name	City	State
Russian Federation	Tatarstan Cancer Cente	Kazan	Tatarstan

Sponsors (1)

Lead Sponsor	Collaborator
Tatarstan Cancer Center

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biochemical Relapse Free Survival Rate	Determine what regime of hypofractionation will be the best 5-10 year biochemical disease free survival. Compare the results of hypofractional regimes (60Gy in 20 farctions; 70 Gy in 28 farctions).	Analysis occurs after all patients have been followed for five year.
Primary	Biochemical Relapse Free Survival Rate	Determine what regime of hypofractionation will be the best 5-10 year biochemical disease free survival. Compare the results of hypofractional regimes (60Gy in 20 farctions; 70 Gy in 28 farctions).	Analysis occurs after all patients have been followed for ten year.
Secondary	Five year Local Progression Rate	Clinical criteria for local recurrence are progression (increase in palpable abnormality) at any time, failure of regression of the palpable tumor by 2 years, and redevelopment of a palpable abnormality after complete disappearance of previous abnormalities. Histologic criteria for local recurrence are presence of prostatic carcinoma upon biopsy and positive biopsy of the palpably normal prostate more than 2 years after the start of treatment. The arms were not statistically compared because of an insufficient number of events.	Analysis occurs after all patients have been followed for five year.
Secondary	Ten year Local Progression Rate	Clinical criteria for local recurrence are progression (increase in palpable abnormality) at any time, failure of regression of the palpable tumor by 2 years, and redevelopment of a palpable abnormality after complete disappearance of previous abnormalities. Histologic criteria for local recurrence are presence of prostatic carcinoma upon biopsy and positive biopsy of the palpably normal prostate more than 2 years after the start of treatment. The arms were not statistically compared because of an insufficient number of events.	Analysis occurs after all patients have been followed for ten year.
Secondary	Five year Overall Survival Rate	Five-year rates Kaplan-Meier estimates. Overall survival (OS) was measured from study entry until the date of death. Patients still alive at the time of analysis were censored at the date of last follow-up	Analysis occurs after all patients have been followed for five year.
Secondary	Ten year Overall Survival Rate	Five-year rates Kaplan-Meier estimates. Overall survival (OS) was measured from study entry until the date of death. Patients still alive at the time of analysis were censored at the date of last follow-up	Analysis occurs after all patients have been followed for ten year.
Secondary	Frequency of Patients With GU and GI Acute and Late Toxicity	The frequency of GU and GI adverse events as defined and graded according to the National Cancer Institute ?TCAE v4 were compared between treatment arms. Acute toxicity was defined as any toxicity beginning within 90 days of completion of RT, and late toxicity was defined as any toxicity beginning more than 90 days after the completion of RT. Acute and late GU and GI toxicity rates were tabulated and reported in two ways: dichotomized as < grade 2 vs = grade 2, and dichotomized as < grade 3 vs = grade 3. Higher grade indicates more severity.	Acute toxicity is measured from start of treatment to 90 days from the completion of treatment. Late toxicity is defined as toxicity occuring after 90 days from completion of treatment. Analysis occured at the time of the primary endpoint analysis.
Secondary	Five year Quality of life measured with EQ5D.	Compare quality of life of patients in 2 groups using the scale EQ5D (European Quality of Life Questionnaire).	Analysis occurs after all patients have been followed for five year.
Secondary	Five year Quality of life measured with EPI? ?P.	Compare quality of life of patients in 2 groups using the scale EPI? ?P (Expanded Prostate Cancer Index Composite for Clinical Practice).	Analysis occurs after all patients have been followed for five year.
Secondary	Ten year Quality of life measured with EQ5D.	.Compare quality of life of patients in 2 groups using the scale EQ5D (European Quality of Life Questionnaire).	Analysis occurs after all patients have been followed for ten year.
Secondary	Ten year Quality of life measured with EPI? ?P.	Compare quality of life of patients in 2 groups using the scale EPI? ?P (Expanded Prostate Cancer Index Composite for Clinical Practice)	Analysis occurs after all patients have been followed for ten year.